Written Question · S7W-04066 · Session 7
What assessment it has made of any barriers that would need to be addressed by Biogen before Skyclarys (omaveloxolone) could be resubmitted…
The question
To ask the Scottish Government what assessment it has made of any barriers that would need to be addressed by Biogen before Skyclarys (omaveloxolone) could be resubmitted to the Scottish Medicines Consortium for consideration for use within NHS Scotland.
The answer
I refer the member to the answer to question S7W-04063 on 19 October 2026. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.The Scottish Medicines Consortium (SMC) appraisal is undertaken independently of Scottish Ministers. Following a not recommended decision, a pharmaceutical company may resubmit the medicine to the SMC. This may involve offering the NHS a lower price for the medicine and/or providing additional evidence to support its clinical and cost effectiveness. The decision on whether to resubmit omaveloxolone (Skyclarys®) to the SMC, and the timing of that resubmission, is entirely one for Biogen to make.
In the Official Report
No contribution in the Official Report cites S7W-04066 by reference.